Surgical management of RANKL-mediated bone tumors is often associated with significant morbidity, particularly for lesions of the face or axial skeleton, and recurrence rates are high after curettage or incomplete resection (5, 9-11). The gene discussed is TNFSF11; the disease is bone neoplasm.